Oslo, January 23, 2019.
Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, Vacc-CRX.
This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors and facilitate virus neutralization.
Lead optimization and drug characterization with Proof of Principle will be established within the next 6 – 9 months.
Bionor’s mission is to identify a functional cure for HIV through the use of two or more vaccines and the immune system. Bionor is the first company, which has successfully completed clinical trials and created a combination of therapeutic vaccines towards a functional cure. The company believes it has the first-mover advantage based on clinical results to date on Vacc-4x, Vacc-C5, and Vacc-CRX.